Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients

Therapeutic Drug Monitoring

Volumn 27, Issue 3, 2005, Pages 315-321

  Armstrong, Victor William ^a   Tenderich, Gero ^b   Shipkova, Maria ^c   Parsa, Amin ^b   Koerfer, Reiner ^b   Schröder, Heike ^d   Oellerich, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c KATHARINENHOSPITAL   (Germany)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Bioavailability; Heart transplantation; Intravenous formulation; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetics

Indexed keywords

CYCLOSPORIN; EDETIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHORIC ACID; PREDNISOLONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CENTRIFUGATION; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG INFUSION; FEMALE; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MALE; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; STEADY STATE; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 20044361837     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000163949.40686.0f     Document Type: Article

References (18)

1. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
2. Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 1999;126:1075-1082.
3. Schutz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999;45: 419-422.
4. Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36: 315-324.
5. Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant. 2000;14:179-188.
6. Fieguth HG, Simon A, Scherer M, et al. Immunosuppressive regimen in lung transplantation: initial intravenous mycophenolate mofetil and cyclosporine avoid cytolytic induction and allow for rapid steroid tapering. Transplant Proc. 2002;34:1879-1880.
7. Kiehl MG, Shipkova M, Basara N, et al. New strategies in GVHD prophylaxis. Bone Marrow Transplant. 2000;25(Suppl 2):S16-S19.
8. Jenke A, Renner U, Richte M, et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant. 2001;15:176-184.
9. Shipkova M, Armstrong VW, Kiehl MG, et al. Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil. Clin Chem. 2001; 47:1485-1488.
10. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators [see comments]. Transplantation. 1998;66:507-515.
11. Shipkova M, Schutz E, Armstrong VW, et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem. 2000;46:365-372.
12. Tsina I, Kaloostian M, Lee R, et al. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma. J Chromatogr B Biomed Appl. 1996;681:347-353.
13. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 1995;17:642-654.
14. Smak GP, van GT, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant. 1999;14:706-708.
15. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit. 2001;23:717-721.
16. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
17. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
18. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.